newsfilter
← Latest News
GlobeNewswire·

ArriVent BioPharma Reports Third Quarter 2026 Financial Results

Continued enrollment in pivotal Phase 3 ALPACCA study in EGFR PACC-mutant NSCLCPresented encouraging Phase 1 data for ARR-217, a CDH17-targeted ADC for gastrointestinal malignancies at ESMODosed first patient in U.S.